

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808157-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Section 1: Identification

Product identifier : Levamisole / Oxfendazole Formulation

Other means of identification : Scanda (A007130)

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

Manufacturer or supplier's details

Company : MSD

Address : 50 Tuas West Drive
Singapore - Singapore 638408

Telephone : +1-908-740-4000

Emergency telephone number : 65 6697 2111 (24/7/365)

E-mail address : EHSDATASTEWARD@msd.com

Section 2: Hazard identification

Classification of the substance or mixture

Reproductive toxicity : Category 1B

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 2

GHS Label elements, including precautionary statements

Hazard pictograms :



Signal word : Danger

Hazard statements : H360FD May damage fertility. May damage the unborn child.
H400 Very toxic to aquatic life.
H411 Toxic to aquatic life with long lasting effects.

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
10808157-00007

Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Precautionary statements

Prevention:

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
levamisole hydrochloride	16595-80-5	>= 3 < 10
oxfendazole	53716-50-0	>= 2.5 < 10
Polyethylene glycol stearate	9004-99-3	>= 1 < 10
Citric acid	77-92-9	>= 1 < 10

Section 4: First-aid measures

Description of necessary first-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808157-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

If swallowed Get medical attention if irritation develops and persists.
: If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed

Risks : May damage fertility. May damage the unborn child.
Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Special protective actions for fire-fighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Levamisole / Oxfendazole FormulationVersion
4.0Revision Date:
14.04.2025SDS Number:
10808157-00007Date of last issue: 06.07.2024
Date of first issue: 05.07.2022**Environmental precautions**

Environmental precautions

- : Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

Methods for cleaning up

- : Soak up with inert absorbent material.
- For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage**Precautions for safe handling**

Technical measures

- : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

- : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling

- : Do not get on skin or clothing.
- Do not breathe mist or vapours.
- Do not swallow.
- Avoid contact with eyes.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
- Keep container tightly closed.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures

- : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808157-00007 Date of last issue: 06.07.2024 Date of first issue: 05.07.2022

Conditions for safe storage, including any incompatibilities

Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection

Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
levamisole hydrochloride	16595-80-5	TWA	20 µg/m ³ (OEB 3)	Internal	
		Further information: Skin			
oxfendazole	53716-50-0	TWA	40 µg/m ³ (OEB 3)	Internal	
		Wipe limit	400 µg/100 cm ²	Internal	
Polyethylene glycol stearate	9004-99-3	PEL (long term)	10 mg/m ³	SG OEL	
		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH	
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH	

Appropriate engineering control measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Individual protection measures, such as personal protective equipment (PPE)

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

Levamisole / Oxfendazole Formulation

Version 4.0	Revision Date: 14.04.2025	SDS Number: 10808157-00007	Date of last issue: 06.07.2024 Date of first issue: 05.07.2022
----------------	------------------------------	-------------------------------	---

	aerosols.
Skin protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Particulates type
Hand protection	
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.

Section 9: Physical and chemical properties

Appearance	: Aqueous solution
Colour	: No data available
Odour	: No data available
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available
Relative density	: No data available

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808157-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Density	: No data available
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available
Particle characteristics	
Particle size	: Not applicable

Section 10: Stability and reactivity

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: Can react with strong oxidizing agents.
Conditions to avoid	: None known.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

Section 11: Toxicological information

Information on likely routes of exposure	: Inhalation Skin contact Ingestion Eye contact
--	--

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	: Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
---------------------	--

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808157-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Components:

levamisole hydrochloride:

Acute oral toxicity	: LD50 (Rat): 180 mg/kg
	LD50 (Mouse): 223 mg/kg
	LD50 (Rabbit): 458 mg/kg
Acute inhalation toxicity	: Remarks: No data available
Acute dermal toxicity	: Remarks: No data available

oxfendazole:

Acute oral toxicity	: LD50 (Rat): > 6,000 mg/kg
	LD50 (Dog): 1,600 mg/kg
	LD50 (sheep): 250 mg/kg

Polyethylene glycol stearate:

Acute oral toxicity	: LD50 (Rat): > 5,000 mg/kg
---------------------	-----------------------------

Citric acid:

Acute oral toxicity	: LD50 (Mouse): 5,400 mg/kg
Acute dermal toxicity	: LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

levamisole hydrochloride:

Remarks	: No data available
---------	---------------------

oxfendazole:

Species	: Rabbit
Result	: No skin irritation

Polyethylene glycol stearate:

Species	: Rabbit
Method	: Draize Test
Result	: No skin irritation

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808157-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Citric acid:

Species	:	Rabbit
Method	:	OECD Test Guideline 404
Result	:	No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

levamisole hydrochloride:

Remarks	:	No data available
---------	---	-------------------

oxfendazole:

Species	:	Rabbit
Result	:	No eye irritation

Polyethylene glycol stearate:

Species	:	Rabbit
Result	:	No eye irritation
Method	:	Draize Test

Citric acid:

Species	:	Rabbit
Result	:	Irritation to eyes, reversing within 21 days
Method	:	OECD Test Guideline 405

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

levamisole hydrochloride:

Remarks	:	No data available
---------	---	-------------------

Polyethylene glycol stearate:

Test Type	:	Open epicutaneous test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Result	:	negative

Germ cell mutagenicity

Not classified based on available information.

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808157-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Components:

levamisole hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

oxfendazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Oral
Result: positive

Polyethylene glycol stearate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: in vitro micronucleus test
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

levamisole hydrochloride:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
NOAEL : 80 mg/kg body weight
Remarks : No significant adverse effects were reported

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808157-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	40 mg/kg body weight
Remarks	:	No significant adverse effects were reported

oxfendazole:

Species	:	Rat
Application Route	:	Oral
Exposure time	:	1 Years
Symptoms	:	No adverse effects
Target Organs	:	Liver

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
Symptoms	:	No adverse effects
Target Organs	:	Liver

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:

levamisole hydrochloride:

Effects on fertility	:	Test Type: Three-generation reproduction toxicity study Species: Rat Application Route: Oral Result: No significant adverse effects were reported
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 20 mg/kg body weight Result: Fetotoxicity
	:	Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 40 mg/kg body weight Result: Fetotoxicity
Reproductive toxicity - Assessment	:	Some evidence of adverse effects on development, based on animal experiments.

oxfendazole:

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat, male Application Route: Oral Fertility: NOAEL: 17 mg/kg body weight
----------------------	---	---

Levamisole / Oxfendazole FormulationVersion
4.0Revision Date:
14.04.2025SDS Number:
10808157-00007Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

		Target Organs: Testes Result: Effects on fertility
		Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Fertility: NOAEL: 0.9 mg/kg body weight Target Organs: Liver Result: No effects on fertility
		Test Type: Fertility Species: Mouse Application Route: Oral Duration of Single Treatment: 1 Months Fertility: NOAEL: 750 mg/kg body weight Target Organs: Testes Result: Effects on fertility
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Fetal effects
		Test Type: Embryo-foetal development Species: Rat Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Embryo-foetal toxicity
		Test Type: Embryo-foetal development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-foetal toxicity, foetal abnormalities
		Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 0.625 mg/kg body weight
Reproductive toxicity - Assessment	:	Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.
Citric acid:		
Effects on foetal development	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
10808157-00007

Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

STOT - single exposure

Not classified based on available information.

Components:

Citric acid:

Assessment : May cause respiratory irritation.

STOT - repeated exposure

Not classified based on available information.

Components:

levamisole hydrochloride:

Target Organs : Blood, Testis
Assessment : May cause damage to organs through prolonged or repeated exposure.

oxfendazole:

Exposure routes : Oral
Target Organs : Liver, Testis
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

levamisole hydrochloride:

Species : Rat
NOAEL : 2.5 mg/kg
Application Route : Oral
Exposure time : 18 Months
Target Organs : Testis

Species : Dog
LOAEL : 20 mg/kg
Application Route : Oral
Exposure time : 18 Months
Target Organs : Blood

Species : Dog
LOAEL : 40 mg/kg
Application Route : Oral
Exposure time : 3 Months

oxfendazole:

Species : Rat
NOAEL : 11 mg/kg
Application Route : Oral

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808157-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Exposure time	:	2 Weeks
Target Organs	:	Blood, Liver, Testis
Species	:	Rat
NOAEL	:	3.8 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Liver, Testis
Species	:	Mouse
NOAEL	:	750 mg/kg
Application Route	:	Oral
Exposure time	:	1 Months
Target Organs	:	Liver
Species	:	Mouse
NOAEL	:	37.5 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Liver
Species	:	Dog
NOAEL	:	6 mg/kg
Application Route	:	Oral
Exposure time	:	1 Months
Remarks	:	No significant adverse effects were reported
Species	:	Dog
NOAEL	:	11 mg/kg
Application Route	:	Oral
Exposure time	:	2 Weeks
Target Organs	:	Lymph nodes, thymus gland
Species	:	Dog
NOAEL	:	13.5 mg/kg
Application Route	:	Oral
Exposure time	:	12 Months
Target Organs	:	Liver

Citric acid:

Species	:	Rat
NOAEL	:	4,000 mg/kg
LOAEL	:	8,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	10 Days

Aspiration toxicity

Not classified based on available information.

Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808157-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Experience with human exposure**Components:****levamisole hydrochloride:**

||| Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension

Section 12: Ecological information**Toxicity****Components:****levamisole hydrochloride:**

||| Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

||| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 64 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

oxfendazole:

||| Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2.7 mg/l
Exposure time: 96 h

LC50 (Oncorhynchus mykiss (rainbow trout)): > 2.5 mg/l
Exposure time: 96 h

||| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.059 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

||| Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

||| M-Factor (Acute aquatic toxicity) : 10

||| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.023 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

||| M-Factor (Chronic aquatic toxicity) : 1

Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808157-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Polyethylene glycol stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 10,000 mg/l
Exposure time: 96 h
Method: DIN 38412

Toxicity to microorganisms : EC10 (Bacteria): > 10,000 mg/l
Exposure time: 16 h

Citric acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,535 mg/l
Exposure time: 24 h

Persistence and degradability**Components:****oxfendazole:**

Stability in water : Hydrolysis: < 5 %(4 d)

Polyethylene glycol stearate:

Biodegradability : Result: Readily biodegradable.
Biodegradation: > 70 %
Exposure time: 10 d
Method: OECD Test Guideline 302B

Citric acid:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Bioaccumulative potential**Components:****oxfendazole:**

Partition coefficient: n-octanol/water : log Pow: 1.95

Citric acid:

Partition coefficient: n-octanol/water : log Pow: -1.72

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808157-00007 Date of last issue: 06.07.2024 Date of first issue: 05.07.2022

Mobility in soil

Components:

oxfendazole:

Distribution among environmental compartments : log Koc: 3.2

Other adverse effects

No data available

Section 13: Disposal considerations

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG

UN number : UN 3082
UN proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(oxfendazole)
Transport hazard class(es) : 9
Packing group : III
Labels : 9
Environmental hazards : yes

IATA-DGR

UN/ID No. : UN 3082
UN proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(oxfendazole)
Transport hazard class(es) : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(oxfendazole)
Transport hazard class(es) : 9

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808157-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

Section 15: Regulatory information

Safety, health and environmental regulations specific for the product in question

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subject to the requirements in the Act/Regulations.

Environmental Protection and Management Act and : Not applicable
Environmental Protection and Management (Hazardous Substances) Regulations
Fire Safety (Petroleum and Flammable Materials) : Not applicable
Regulations

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

Section 16: Other information

Revision Date : 14.04.2025

Further information

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD compile the Safety Data eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/> Sheet

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
SG OEL : Singapore. Workplace Safety and Health (General Provisions) Regulations - First Schedule Permissible Exposure Limits of Toxic Substances.

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0	Revision Date: 14.04.2025	SDS Number: 10808157-00007	Date of last issue: 06.07.2024 Date of first issue: 05.07.2022
----------------	------------------------------	-------------------------------	---

ACGIH / TWA : 8-hour, time-weighted average
SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN